These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17803746)

  • 1. Pharmacokinetics and pharmacodynamics of a single dose of zoledronate in healthy dogs.
    Martín-Jiménez T; De Lorimier LP; Fan TM; Freise KJ
    J Vet Pharmacol Ther; 2007 Oct; 30(5):492-5. PubMed ID: 17803746
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months.
    Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Callon KE; Gamble GD; Reid IR
    J Bone Miner Res; 2008 Aug; 23(8):1304-8. PubMed ID: 18627266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacokinetics of two intravenous administration regimens of tiludronate in healthy adult horses and effects on the bone resorption marker CTX-1.
    Delguste C; Amory H; Guyonnet J; Thibaud D; Garnero P; Detilleux J; Lepage OM; Doucet M
    J Vet Pharmacol Ther; 2008 Apr; 31(2):108-16. PubMed ID: 18307502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis].
    Tanaka M; Mori H; Shimizu K; Toshiyuki ; Matsuoka ; Yamamotoya H; Minamide T; Mori M; Nozaki K; Usui T; Shimokawa K; Suzuki H; Aoyama K; Kimoto A; Sasamata M; Miyata K
    Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):149-57. PubMed ID: 19749488
    [No Abstract]   [Full Text] [Related]  

  • 5. A once-yearly IV bisphosphonate for osteoporosis.
    Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523
    [No Abstract]   [Full Text] [Related]  

  • 6. [Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
    MMW Fortschr Med; 2006 Jun; 148(25):60-1. PubMed ID: 16859169
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics, pharmacodynamics, and safety of zoledronic acid in horses.
    Nieto JE; Maher O; Stanley SD; Knych HK; Snyder JR
    Am J Vet Res; 2013 Apr; 74(4):550-6. PubMed ID: 23531062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone metabolic effects of single-dose zoledronate in healthy dogs.
    de Lorimier LP; Fan TM
    J Vet Intern Med; 2005; 19(6):924-7. PubMed ID: 16355693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and therapeutic efficacy of intrapulmonary administration of zoledronate for the prevention of bone destruction in rheumatoid arthritis.
    Katsumi H; Mozume T; Yanagi S; Hasei T; Watanabe T; Sakane T; Yamamoto A
    J Drug Target; 2016; 24(6):530-6. PubMed ID: 26508267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal remodeling following clinically relevant radiation-induced bone damage treated with zoledronic acid.
    Hui SK; Fairchild GR; Kidder LS; Sharma M; Bhattacharya M; Jackson S; Le C; Yee D
    Calcif Tissue Int; 2012 Jan; 90(1):40-9. PubMed ID: 22083107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic zoledronate precoating of a bone graft reduces bone resorption during remodeling.
    Tägil M; Aspenberg P; Astrand J
    Acta Orthop; 2006 Feb; 77(1):23-6. PubMed ID: 16534698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution and plasma protein binding of zoledronic acid.
    Weiss HM; Pfaar U; Schweitzer A; Wiegand H; Skerjanec A; Schran H
    Drug Metab Dispos; 2008 Oct; 36(10):2043-9. PubMed ID: 18625688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics of Zoledronic acid[once-yearly bisphosphonate(intravenous infusion)].].
    Tanaka S
    Clin Calcium; 2016; 26(11):1605-1613. PubMed ID: 27777393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis.
    Fan TM; de Lorimier LP; Garrett LD; Lacoste HI
    J Vet Intern Med; 2008; 22(2):380-7. PubMed ID: 18346146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of transient osteoporosis with intravenous zoledronate: a case report.
    Maslin D; Karanth M; Bhagat S; Guirguis R
    Int J Rheum Dis; 2014 Sep; 17(7):816-7. PubMed ID: 24673857
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of bisphosphonates on sutural bone formation and relapse: A histologic and immunohistochemical study.
    Oztürk F; Babacan H; Inan S; Gümüş C
    Am J Orthod Dentofacial Orthop; 2011 Jul; 140(1):e31-41. PubMed ID: 21724069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis.
    Voskaridou E; Christoulas D; Antoniadou L; Terpos E
    Acta Haematol; 2008; 119(1):40-4. PubMed ID: 18253025
    [No Abstract]   [Full Text] [Related]  

  • 18. Non-persistent effect of short-term bisphosphonate treatment in preventing fractures after liver transplantation.
    Bodingbauer M; Pakrah B; Kristo I; Marschalek J; Burghuber C; Györi G; Kainz A; Rasoul-Rockenschaub S; Klaushofer K; Muehlbacher F; Oberbauer R
    Transpl Int; 2010 Jan; 23(1):118-20. PubMed ID: 19624497
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmacological profile and clinical evidence in patients with primary osteoporosis treated with intravenous ibandronate].
    Shiraishi A
    Nihon Yakurigaku Zasshi; 2014 Jun; 143(6):302-9. PubMed ID: 24919557
    [No Abstract]   [Full Text] [Related]  

  • 20. Bisphosphonate therapy and dental treatment.
    Phillips G
    J Indiana Dent Assoc; 2007-2008 Winter; 86(4):4-8. PubMed ID: 18363257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.